Alejandra Barunda

But the drugs have been in short supply thanks to really unprecedented demand, which has allowed this sort of strange thing to happen, which is that pharmacies can essentially make copies of brand-name drugs when those medicines are in short supply. And that process, which is different from the production of generic drugs, is called compounding. That's so cool.

But the drugs have been in short supply thanks to really unprecedented demand, which has allowed this sort of strange thing to happen, which is that pharmacies can essentially make copies of brand-name drugs when those medicines are in short supply. And that process, which is different from the production of generic drugs, is called compounding. That's so cool.

But the drugs have been in short supply thanks to really unprecedented demand, which has allowed this sort of strange thing to happen, which is that pharmacies can essentially make copies of brand-name drugs when those medicines are in short supply. And that process, which is different from the production of generic drugs, is called compounding. That's so cool.

But they've also been a lifeline for patients whose doctors have prescribed these drugs for them, but their insurance won't cover them. So instead of paying more than $1,000 out of pocket a month, they can pay a few hundred, which is still expensive, but at least somewhat more manageable. But it's not a permanent solution.

But they've also been a lifeline for patients whose doctors have prescribed these drugs for them, but their insurance won't cover them. So instead of paying more than $1,000 out of pocket a month, they can pay a few hundred, which is still expensive, but at least somewhat more manageable. But it's not a permanent solution.

But they've also been a lifeline for patients whose doctors have prescribed these drugs for them, but their insurance won't cover them. So instead of paying more than $1,000 out of pocket a month, they can pay a few hundred, which is still expensive, but at least somewhat more manageable. But it's not a permanent solution.

Once the shortages end, and they will eventually, the compounders will have to stop. There's really been a ton of back and forth about that. One drug was taken off the shortage list but might go back on again. Patients who rely on the compounded versions are confused and scared and stockpiling, and it's a mess. Where do you see all this going next year in 2025?

Once the shortages end, and they will eventually, the compounders will have to stop. There's really been a ton of back and forth about that. One drug was taken off the shortage list but might go back on again. Patients who rely on the compounded versions are confused and scared and stockpiling, and it's a mess. Where do you see all this going next year in 2025?

Once the shortages end, and they will eventually, the compounders will have to stop. There's really been a ton of back and forth about that. One drug was taken off the shortage list but might go back on again. Patients who rely on the compounded versions are confused and scared and stockpiling, and it's a mess. Where do you see all this going next year in 2025?

I think demand is only going to grow, but I think access looks like it's going to continue to be a problem, especially as the compounding situation winds down. insurance coverage is still an issue. The price is still an issue.

I think demand is only going to grow, but I think access looks like it's going to continue to be a problem, especially as the compounding situation winds down. insurance coverage is still an issue. The price is still an issue.

I think demand is only going to grow, but I think access looks like it's going to continue to be a problem, especially as the compounding situation winds down. insurance coverage is still an issue. The price is still an issue.

The Biden administration also proposed a new rule that would extend Medicare and Medicaid coverage to include obesity drugs like Wagovi and Zepbound, which is another one of these, though it will be up to the Trump administration to decide whether or how to implement that. Meanwhile, the drugs got approved to do new things like lower the risk of heart attack in some patients. Wow.

The Biden administration also proposed a new rule that would extend Medicare and Medicaid coverage to include obesity drugs like Wagovi and Zepbound, which is another one of these, though it will be up to the Trump administration to decide whether or how to implement that. Meanwhile, the drugs got approved to do new things like lower the risk of heart attack in some patients. Wow.

The Biden administration also proposed a new rule that would extend Medicare and Medicaid coverage to include obesity drugs like Wagovi and Zepbound, which is another one of these, though it will be up to the Trump administration to decide whether or how to implement that. Meanwhile, the drugs got approved to do new things like lower the risk of heart attack in some patients. Wow.

And that very well may continue into 2025 and beyond as the research continues. On the flip side, we may learn about new side effects as more people take these drugs for longer.

And that very well may continue into 2025 and beyond as the research continues. On the flip side, we may learn about new side effects as more people take these drugs for longer.

And that very well may continue into 2025 and beyond as the research continues. On the flip side, we may learn about new side effects as more people take these drugs for longer.